Skip to content

Study · Observational study · n = 376 · 2026

3 results

Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.

AlTaweel MO, Al Makhloof S, AlKhayyal AK, Alrashada J, AlOhaymid M, Alshahrani A, Alarfaj AW, Alqarni TA, Al Moaibed G, Altharman NM

Expert review of cardiovascular therapy2 Aug 2026

PMID42535667 (opens in a new tab)DOI10.1080/14779072.2026.2713476 (opens in a new tab)PepBankPUB-42535667
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults prescribed dapagliflozin, adding semaglutide was not associated with a significant difference in HF/MI-related clinical status versus dapagliflozin alone (adjusted RR 0.787).

    In plain wordsIn adults taking dapagliflozin, adding semaglutide was not linked to a significant difference in heart failure or heart attack status.

    Peptide
    Semaglutide
    Outcome
    No significant changeHeart failure or myocardial infarction related clinical status
    Study

    n = 376

    Comparator
    Dapagliflozin alone
    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Adjusted risk ratio
    0.787
    dapagliflozin plus semaglutide versus dapagliflozin

    Source sentences

    Summary
    Combination therapy was not associated with a statistically significant difference in recorded HF/MI-related clinical status (adjusted RR 0.787; 95% bootstrap CI 0.320-1.813; p = 0.516).
    2 context sentences
    Summary · context
    We conducted a retrospective cohort study of 376 adults prescribed dapagliflozin, with or without semaglutide, at a Saudi tertiary hospital (2020-2024).
    Summary · context
    Inverse probability of treatment weighting and causal mediation analysis evaluated whether ΔeGFR mediated treatment-outcome associations during 90-365days of follow-up.
  2. 02HumanObservational studyMechanism

    In adults prescribed dapagliflozin, early change in eGFR showed minimal mediation of the association between adding semaglutide and HF/MI-related outcomes.

    In plain wordsIn adults taking dapagliflozin, early kidney function changes explained very little of any link between adding semaglutide and heart outcomes.

    Peptide
    Semaglutide
    Outcome
    No significant changeMediation of HF/MI outcomes by early change in eGFR
    Study

    n = 376

    Comparator
    Dapagliflozin alone
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Indirect risk ratio
    1.013
    eGFR mediation

    Source sentences

    Summary
    ΔeGFR showed minimal mediation (indirect RR 1.013; 95% CI 0.901-1.165).
    2 context sentences
    Summary · context
    We conducted a retrospective cohort study of 376 adults prescribed dapagliflozin, with or without semaglutide, at a Saudi tertiary hospital (2020-2024).
    Summary · context
    Inverse probability of treatment weighting and causal mediation analysis evaluated whether ΔeGFR mediated treatment-outcome associations during 90-365days of follow-up.
  3. 03HumanObservational studyEfficacy outcome

    In adults prescribed dapagliflozin, inverse probability weighted analyses showed a neutral composite HF/MI result for adding semaglutide versus dapagliflozin alone (RR 1.12).

    In plain wordsIn adults taking dapagliflozin, a second analysis also found no clear difference in heart outcomes when semaglutide was added.

    Peptide
    Semaglutide
    Outcome
    No significant changeComposite HF/MI outcome in IPTW analysis
    Study

    n = 376

    Comparator
    Dapagliflozin alone
    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Composite risk ratio
    1.12
    IPTW analysis

    Source sentences

    Summary
    IPTW analyses yielded similar neutral findings (composite RR 1.12; 95% CI 0.47-2.66).
    2 context sentences
    Summary · context
    We conducted a retrospective cohort study of 376 adults prescribed dapagliflozin, with or without semaglutide, at a Saudi tertiary hospital (2020-2024).
    Summary · context
    Inverse probability of treatment weighting and causal mediation analysis evaluated whether ΔeGFR mediated treatment-outcome associations during 90-365days of follow-up.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.